Peptides as the next generation of anti-infectives

Future Medicinal Chemistry

Volumn 5, Issue 3, 2013, Pages 315-337

  Mercer, Derry K ^a   Oneil, Deborah A ^a  

^a NOVABIOTICS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; BACTERIOCIN; BATTACIN; BLEOMYCIN; BRILACIDIN; C16G2; COLISTIN; DALBAVANCIN; DAPTOMYCIN; DPK 060; EMPEDOPEPTIN; ENFUVIRTIDE; GOMESIN; HLF1 11; LANTIBIOTIC; MX 2401; NISIN; NOVEXATIN; NVB 302; NZ 2114; OMIGANAN; PEDIOCIN; PEXIGANAN; POL 7080; POLYPEPTIDE ANTIBIOTIC AGENT; PXL 01; TEICOPLANIN; TELAVANCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; WAP 8294A;

ANTIFUNGAL ACTIVITY; BIOFILM; CANDIDA ALBICANS; CLINICAL PRACTICE; ENZYME LINKED IMMUNOSORBENT ASSAY; HELICOBACTER PYLORI; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VENTILATOR ASSOCIATED PNEUMONIA;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIA; BACTERIAL INFECTIONS; DRUG DISCOVERY; FUNGI; HUMANS; MOLECULAR SEQUENCE DATA; MYCOSES; PARASITIC DISEASES; VIRUS DISEASES; VIRUSES;

EID: 84874687957     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.213     Document Type: Review

References (181)

1. Wang G, Li X, Wang Z. APD2: the updated antimicrobial peptide database and its application in peptide design. Nucleic Acids Res. 37(Database issue), D933-D937 (2009).
2. Jenssen H, Hamill P, Hancock RE. Peptide antimicrobial agents. Clin. Microbiol. Rev. 19(3), 491-511 (2006).
3. Park Y, Hahm KS. Antimicrobial peptides (AMPs): peptide structure and mode of action. J. Biochem. Mol. Biol. 38(5), 507-516 (2005).
4. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat. Rev. 3(9), 710-720 (2003).
5. Mcphee JB, Hancock RE. Function and therapeutic potential of host defence peptides. J. Pept. Sci. 11(11), 677-687 (2005).
6. Fjell CD, Hiss JA, Hancock RE, Schneider G. Designing antimicrobial peptides: form follows function. Nat. Rev. Drug Discov. 11(1), 37-51 (2012).
7. Canton R, Morosini MI. Emergence and spread of antibiotic resistance following exposure to antibiotics. FEMS Microbiol. Rev. 35(5), 977-991 (2011).
8. French GL. The continuing crisis in antibiotic resistance. Int. J. Antimicrob. Agents 36(Suppl. 3), S3-S7 (2010).
9. Gottlieb T, Nimmo GR. Antibiotic resistance is an emerging threat to public health: an urgent call to action at the Antimicrobial Resistance Summit 2011. Med. J. Aust. 194(6), 281-283 (2011).
10. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev. 74(3), 417-433 (2010).
11. Boucher HW. Challenges in anti-infective development in the era of bad bugs, no drugs: a regulatory perspective using the example of bloodstream infection as an indication. Clin. Infect. Dis. 50(Suppl. 1), S4-S9 (2010).
12. Spellberg B, Guidos R, Gilbert D et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46(2), 155-164 (2008).
13. Milletti F. Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov. Today 17(15-16), 850-860 (2012).
14. Yount NY, Bayer AS, Xiong YQ, Yeaman MR. Advances in antimicrobial peptide immunobiology. Biopolymers 84(5), 435-458 (2006).
15. Eckert R. Road to clinical efficacy: challenges and novel strategies for antimicrobial peptide development. Future Microbol. 6(6), 635-651 (2011).
16. Labonte J, Lebbos J, Kirkpatrick P. Enfuvirtide. Nat. Rev. Drug Discov. 2(5), 345-346 (2003).
17. Lax R. The future of peptide development in the pharmaceutical industry. PharMf. September, 10-15 (2010).
18. Vergote V, Burvenich C, Van De Wiele C, De Spiegeleer B. Quality specifications for peptide drugs: a regulatory-pharmaceutical approach. J. Pept. Sci. 15(11), 697-710 (2009).
19. Brogden NK, Brogden KA. Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals? Int. J. Antimicrob. Agents 38(3), 217-225 (2011).
20. Morris CJ, Beck K, Fox MA, Ulaeto D, Clark GC, Gumbleton M. PEGylation of antimicrobial peptides maintains the active peptide conformation, model membrane interactions, and antimicrobial activity while improving lung tissue biocompatibility following airway delivery. Antimicrob. Agents Chemother. 56(6), 3298-3308 (2012).
21. Tossi A, Sandri L, Giangaspero A. Amphipathic, alpha-helical antimicrobial peptides. Biopolymers 55(1), 4-30 (2000).
22. Matsuzaki K. Control of cell selectivity of antimicrobial peptides. Acta Biochim. Biophys. 1788(8), 1687-1692 (2009).
23. Pasupuleti M, Schmidtchen A, Chalupka A, Ringstad L, Malmsten M. End-tagging of ultra-short antimicrobial peptides by W/F stretches to facilitate bacterial killing. PLoS ONE 4(4), e5285 (2009).
24. Ewles M, Goodwin L. Bioanalytical approaches to analyzing peptides and proteins by LC-MS/MS. Bioanalysis 3(12), 1379-1397 (2011).
25. Corrales J, Gordon WL, Noga EJ. Development of an ELISA for quantification of the antimicrobial peptide piscidin 4 and its application to assess stress in fish. Fish Shellfish Immunol. 27(2), 154-163 (2009).
26. Davidopoulou S, Diza E, Menexes G, Kalfas S. Salivary concentration of the antimicrobial peptide LL-37 in children. Arch. Oral Biol. 57(7), 865-869 (2012).
27. Hui Y, Wohlers J, Podschun R et al. Antimicrobial peptides in nasal secretion and mucosa with respect to S. aureus colonisation in Wegener s granulomatosis. Clin. Exp. Rheumatol. 29(1 Suppl. 64), S49-S56 (2011).
28. Wu G, Wang S, Wang X et al. Determination of a new antibacterial peptide S-thanatin in rat plasma by an indirected-ELISA. Peptides 32(7), 1484-1487 (2011).
29. Shirin T, Rahman A, Danielsson A et al. Antimicrobial peptides in the duodenum at the acute and convalescent stages in patients with diarrhea due to Vibrio cholerae O1 or enterotoxigenic Escherichia coli infection. Microbes Infect. 13(12-13), 1111-1120 (2011).
30. Chang D, Kolis SJ, Linderholm KH et al. Bioanalytical method development and validation for a large peptide HIV fusion inhibitor (Enfuvirtide, T-20) and its metabolite in human plasma using LC-MS/MS. J. Pharm. Biomed. Anal. 38(3), 487-496 (2005).
31. Kelley WP, Chen S, Floyd PD et al. Analytical characterization of an orally-delivered peptide pharmaceutical product. Anal. Chem. 84(10), 4357-4372 (2012).
32. Juneja VK, Dwivedi HP, Yan X. Novel natural food antimicrobials. Annu. Rev. Food Sci. Technol. 3, 381-403 (2012).
33. Eckmann C, Dryden M. Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin. Eur. J. Med. Res. 15(12), 554-563 (2010).
34. Nation RL, Li J. Colistin in the 21st century. Curr. Opin. Infect. Dis. 22(6), 535-543 (2009).
35. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23(1), 99-139 (2010).
36. Koprivnjak T, Peschel A. Bacterial resistance mechanisms against host defense peptides. Cell. Mol. Life Sci. 68(13), 2243-2254 (2011).
37. Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J. Antimicrob. Chemother. 67(7), 1607-1615 (2012).
38. Vilhena C, Bettencourt A. Daptomycin: a review of properties, clinical use, drug delivery and resistance. Mini Rev. Med. Chem. 12(3), 202-209 (2012).
39. Calfee DP. Methicillin-resistant Staphylococcus aureus and vancomycinresistant enterococci, and other Grampositives in healthcare. Curr. Opin. Infect. Dis. 25(4), 385-394 (2012).
40. Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur. J. Clin. Pharmacol. 68(9), 1243-1255 (2012).
41. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit. Care 10(1), R27 (2006).
42. Nagarajan R. Antibacterial activities and modes of action of vancomycin and related glycopeptides. Antimicrob. Agents Chemother. 35(4), 605-609 (1991).
43. Rivera AM, Boucher HW. Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci. Mayo Clin. Proc. 86(12), 1230-1243 (2011).
44. Shah D, Dang MD, Hasbun R et al. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev. Anti Infect. Ther. 8(5), 555-564 (2010).
45. Reynolds PE. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur. J. Clin. Microbiol. Infect. Dis. 8(11), 943-950 (1989).
46. Fang X, Nam J, Shin D, Rew Y, Boger DL, Walker S. Functional and biochemical analysis of a key series of ramoplanin analogues. Bioorg. Med. Chem. Lett. 19(21), 6189-6191 (2009).
47. Seam P, Janik JE, Longo DL, Devita VT Jr. Role of chemotherapy in Hodgkin's lymphoma. Cancer J. 15(2), 150-154 (2009.
48. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin. Infect. Dis. 40(9), 1333-1341 (2005).
49. Paterson DL. Impact of antibiotic resistance in Gram-negative bacilli on empirical and definitive antibiotic therapy. Clin. Infect. Dis. 47(Suppl. 1), S14-S20 (2008).
50. Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrugresistant pathogens: a critical review. J. Antimicrob. Chemother. 60(6), 1206-1215 (2007).
51. Kwa AL, Tam VH, Falagas ME. Polymyxins: a review of the current status including recent developments. Ann. Acad. Med. Singap. 37(10), 870-883 (2008).
52. Robbel L, Marahiel MA. Daptomycin, a bacterial lipopeptide synthesized by a nonribosomal machinery. J. Biol. Chem. 285(36), 27501-27508 (2010).
53. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J. Antimicrob. Chemother. 55(3), 283-288 (2005).
54. Qian CD, Wu XC, Teng Y et al. Battacin (Octapeptin B5), a new cyclic lipopeptide antibiotic from Paenibacillus tianmuensis active against multidrug-resistant Gramnegative bacteria. Antimicrob. Agents Chemother. 56(3), 1458-1465 (2012).
55. Vaara M. Polymyxins and their novel derivatives. Curr. Opin. Microbiol. 13(5), 574-581 (2010).
56. Dugourd D, Yang H, Elliott M et al. Antimicrobial properties of MX-2401, an expanded-spectrum lipopeptide active in the presence of lung surfactant. Antimicrob. Agents Chemother. 55(8), 3720-3728 (2011).
57. Konishi M, Sugawara K, Hanada M et al. Empedopeptin (BMY-28117), a new depsipeptide antibiotic. I. Production, isolation and properties. J. Antibiot. 37(9), 949-957 (1984).
58. Kato A, Nakaya S, Kokubo N et al. A new anti-MRSA antibiotic complex, WAP-8294A. I. Taxonomy, isolation and biological activities. J. Antibiot. 51(10), 929-935 (1998).
59. Raaijmakers JM, De Bruijn I, Nybroe O, Ongena M. Natural functions of lipopeptides from Bacillus and Pseudomonas: more than surfactants and antibiotics. FEMS Microbiol. Rev. 34(6), 1037-1062 (2010).
60. Nishie M, Nagao J, Sonomoto K. Antibacterial peptides 'bacteriocins': an overview of their diverse characteristics and applications. Biocontrol Sci. 17(1), 1-16 (2012).
61. Lee H, Kim HY. Lantibiotics, class I bacteriocins from the genus Bacillus. J. Microbiol. Biotechnol. 21(3), 229-235 (2011).
62. Lubelski J, Rink R, Khusainov R, Moll GN, Kuipers OP. Biosynthesis, immunity, regulation, mode of action and engineering of the model lantibiotic nisin. Cell. Mol. Life Sci. 65(3), 455-476 (2008).
63. Hasper HE, Kramer NE, Smith JL et al. An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II. Science 313(5793), 1636-1637 (2006).
64. Papagianni M, Anastasiadou S. Pediocins: the bacteriocins of Pediococci. Sources, production, properties and applications. Microb. Cell Fact. 8, 3 (2009).
65. Pettit RS, Johnson CE. Airway-rehydrating agents for the treatment of cystic fibrosis: past, present, and future. Ann. Pharmacother. 45(1), 49-59 (2011).
66. Scholl D, Martin DW Jr. Antibacterial efficacy of R-type pyocins towards Pseudomonas aeruginosa in a murine peritonitis model. Antimicrob Agents Chemother 52(5), 1647-1652 (2008).
67. Ritchie JM, Greenwich JL, Davis BM et al. An Escherichia coli O157-specific engineered pyocin prevents and ameliorates infection by E. coli O157:H7 in an animal model of diarrheal disease. Antimicrob. Agents Chemother. 55(12), 5469-5474 (2011).
68. Fritsche TR, Rhomberg PR, Sader HS, Jones RN. Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheterassociated infections. Antimicrob. Agents Chemother. 52(3), 1187-1189 (2008).
69. Fritsche TR, Rhomberg PR, Sader HS, Jones RN. Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections. J. Antimicrob. Chemother. 61(5), 1092-1098 (2008).
70. Ge Y, Macdonald D, Henry MM et al. In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers. Diagn. Microbiol. Infect. Dis. 35(1), 45-53 (1999).
71. Lipsky BA, Holroyd KJ, Zasloff M. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin. Infect. Dis. 47(12), 1537-1545 (2008).
72. Kollef M, Pittet D, Sanchez Garcia M et al. A randomized double-blind trial of iseganan in prevention of ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 173(1), 91-97 (2006).
73. Elad S, Epstein JB, Raber-Durlacher J, Donnelly P, Strahilevitz J. The antimicrobial effect of Iseganan HCl oral solution in patients receiving stomatotoxic chemotherapy: analysis from a multicenter, double-blind, placebo-controlled, randomized, Phase III clinical trial. J. Oral Pathol. Med. 41(3), 229-234 (2012).
74. Srinivas N, Jetter P, Ueberbacher B et al. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science 327, 1010-1013 (2010).
75. Ostergaard C, Sandvang D, Frimodt-Moller N, Kristensen HH. High cerebrospinal fluid (CSF) penetration and potent bactericidal activity in CSF of NZ2114, a novel plectasin variant, during experimental pneumococcal meningitis. Antimicrob. Agents Chemother. 53(4), 1581-1585 (2009).
76. Xiong YQ, Hady WA, Deslandes A et al. Eff?icacy of NZ2114, a novel plectasin-derived cationic antimicrobial peptide antibiotic, in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 55(11), 5325-5330 (2011).
77. Sajjan US, Tran LT, Sole N et al. P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients. Antimicrob. Agents Chemother. 45(12), 3437-3444 (2001).
78. Nordahl EA, Rydengard V, Morgelin M, Schmidtchen A. Domain 5 of high molecular weight kininogen is antibacterial. J. Biol. Chem. 280(41), 34832-34839 (2005).
79. Nijnik A, Hancock RE. The roles of cathelicidin LL-37 in immune defences and novel clinical applications. Curr. Opin. Hematol. 16(1), 41-47 (2009).
80. Wiig M, Olmarker K, Hakansson J, Ekstrom L, Nilsson E, Mahlapuu M. A lactoferrin-derived peptide (PXL01) for the reduction of adhesion formation in flexor tendon surgery: an experimental study in rabbits. J. Hand Surg. Eur. Vol. 36(8), 656-662 (2011).
81. Brouwer CP, Rahman M, Welling MM. Discovery and development of a synthetic peptide derived from lactoferrin for clinical use. Peptides 32(9), 1953-1963 (2011).
82. Scott RW, Degrado WF, Tew GN. De novo designed synthetic mimics of antimicrobial peptides. Curr. Opin. Biotechnol. 19(6), 620-627 (2008).
83. Kaplan CW, Sim JH, Shah KR, Kolesnikova A, Shi W, Eckert R. Selective membrane disruption: the mode of action of C16G2, a specifically-targeted antimicrobial peptide. Antimicrob. Agents Chemother. 55(7), 3446-3452 (2011).
84. Sullivan R, Santarpia P, Lavender S et al. Clinical efficacy of a specifically targeted antimicrobial peptide mouth rinse: targeted elimination of Streptococcus mutans and prevention of demineralization. Caries Res. 45(5), 415-428 (2011).
85. Isaksson J, Brandsdal BO, Engqvist M, Flaten GE, Svendsen JS, Stensen W. A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption. J. Med. Chem. 54(16), 5786-5795 (2011).
86. Scheicher S, Zhang L, Falla T. Lipohexapeptide HB1345: A novel anti-infective for acne. Presented at: American Academy of Dermatology Meeting. Chicago, IL, USA, 30 July-3 August 2008.
87. Mookherjee N, Rehaume LM, Hancock RE. Cathelicidins and functional analogues as antisepsis molecules. Expert Opin. Ther. Targets 11(8), 993-1004 (2007).
88. Scott MG, Dullaghan E, Mookherjee N et al. An anti-infective peptide that selectively modulates the innate immune response. Nat. Biotechnol. 25(4), 465-472 (2007).
89. Yu HB, Kielczewska A, Rozek A et al. Sequestosome-1/p62 is the key intracellular target of innate defense regulator peptide. J. Biol. Chem. 284(52), 36007-36011 (2009).
90. Gudmundsson GH, Bergman P, Andersson J, Raqib R, Agerberth B. Battle and balance at mucosal surfaces - the story of Shigella and antimicrobial peptides. Biochem. Biophys. Res. Commun. 396(1), 116-119 (2010).
91. Muralidharan R, Bobek LA. Antifungal activity of human salivary mucin-derived peptide, MUC7 12-mer, in a murine model of oral candidiasis. J. Pept. Res. 66(Suppl. 1), 82-89 (2005).
92. Rossi DC, Munoz JE, Carvalho DD et al. Therapeutic use of a cationic antimicrobial peptide from the spider Acanthoscurria gomesiana in the control of experimental candidiasis. BMC Microbiol. 12, 28 (2012).
93. Nikawa H, Fukushima H, Makihira S, Hamada T, Samaranayake LP. Fungicidal effect of three new synthetic cationic peptides against Candida albicans. Oral Dis. 10(4), 221-228 (2004).
94. Rossignol T, Kelly B, Dobson C, D'enfert C. Endocytosis-mediated vacuolar accumulation of the human ApoE apolipoprotein-derived ApoEdpL-W antimicrobial peptide contributes to its antifungal activity in Candida albicans. Antimicrob. Agents Chemother. 55(10), 4670-4681 (2011).
95. Wagener J, Schneider JJ, Baxmann S et al. A peptide derived from the highly conserved protein GAPDH is involved in tissue protection by different antifungal strategies and epithelial immunomodulation. J. Invest. Dermatol. 1311, 144-153 (2012).
96. Munoz A, Lopez-Garcia B, Perez-Paya E, Marcos JF. Antimicrobial properties of derivatives of the cationic tryptophan-rich hexapeptide PAF26. Biochem. Biophys. Res. Commun. 354(1), 172-177 (2007).
97. Munoz A, Marcos JF, Read ND. Concentration-dependent mechanisms of cell penetration and killing by the de novo designed antifungal hexapeptide PAF26. Mol. Microbiol. 85(1), 89-106 (2012).
98. Carmona L, Gandia M, Lopez-Garcia B, Marcos JF. Sensitivity of Saccharomyces cerevisiae to the cell-penetrating antifungal peptide PAF26 correlates with endogenous nitric oxide (NO) production. Biochem. Biophys. Res. Commun. 417(1), 56-61 (2012).
99. Burrows LL, Stark M, Chan C, Glukhov E, Sinnadurai S, Deber CM. Activity of novel non-amphipathic cationic antimicrobial peptides against Candida species. J. Antimicrob. Chemother. 57(5), 899-907 (2006).
100. Stark M, Liu LP, Deber CM. Cationic hydrophobic peptides with antimicrobial activity. Antimicrob. Agents Chemother. 46(11), 3585-3590 (2002).
101. Sonthi M, Toubiana M, Pallavicini A, Venier P, Roch P. Diversity of coding sequences and gene structures of the antifungal peptide mytimycin (MytM) from the Mediterranean mussel, Mytilus galloprovincialis. Mar. Biotechnol. (NY) 13(5), 857-867 (2011).
102. Lopez-Abarrategui C, Alba A, Silva ON et al. Functional characterization of a synthetic hydrophilic antifungal peptide derived from the marine snail Cenchritis muricatus. Biochimie 94(4), 968-974 (2012).
103. Pushpanathan M, Rajendhran J, Jayashree S, Sundarakrishnan B, Jayachandran S, Gunasekaran P. Identification of a novel antifungal peptide with chitin-binding property from marine metagenome. Protein Pept. Lett. 19(12), 1289-1296 (2012).
104. Park C, Lee DG. Fungicidal effect of antimicrobial peptide arenicin-1. Biochim. Biophys. Acta 1788(9), 1790-1796 (2009).
105. Cho J, Lee DG. The antimicrobial peptide arenicin-1 promotes generation of reactive oxygen species and induction of apoptosis. Biochim. Biophys. Acta 1810(12), 1246-1251 (2011).
106. Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc. Natl Acad. Sci. USA 84(15), 5449-5453 (1987).
107. Park Y, Lee DG, Hahm KS. HP(2-9)- magainin 2(1-12), a synthetic hybrid peptide, exerts its antifungal effect on Candida albicans by damaging the plasma membrane. J. Pept. Sci. 10(4), 204-209 (2004).
108. Simmaco M, Barra D, Chiarini F et al. A family of bombinin-related peptides from the skin of Bombina variegata. Eur. J. Biochem. 199(1), 217-222 (1991).
109. Simmaco M, Kreil G, Barra D. Bombinins, antimicrobial peptides from Bombina species. Biochim. Biophys. Acta 1788(8), 1551-1555 (2009).
110. Pal T, Abraham B, Sonnevend A, Jumaa P, Conlon JM. Brevinin-1BYa: a naturally occurring peptide from frog skin with broad-spectrum antibacterial and antifungal properties. Int. J. Antimicrob. Agents 27(6), 525-529 (2006).
111. Hwang B, Hwang JS, Lee J, Lee DG. Antifungal properties and mode of action of psacotheasin, a novel knottin-type peptide derived from Psacothea hilaris. Biochem. Biophys. Res. Commun. 400(3), 352-357 (2010).
112. Jang WS, Kim HK, Lee KY, Kim SA, Han YS, Lee IH. Antifungal activity of synthetic peptide derived from halocidin, antimicrobial peptide from the tunicate, Halocynthia aurantium. FEBS Lett. 580(5), 1490-1496 (2006).
113. Lee YS, Shin YP, Shin SH, Park S, Kim MH, Lee IH. Therapeutic efficacy of halocidinderived peptide HG1 in a mouse model of surgical wound infection with methicillinresistant Staphylococcus aureus. Antimicrob. Agents Chemother. 55(3), 1296-1299 (2011).
114. Silva PI Jr, Daffre S, Bulet P. Isolation and characterization of gomesin, an 18-residue cysteine-rich defense peptide from the spider Acanthoscurria gomesiana hemocytes with sequence similarities to horseshoe crab antimicrobial peptides of the tachyplesin family. J. Biol. Chem. 275(43), 33464-33470 (2000).
115. Barbosa FM, Daffre S, Maldonado RA, Miranda A, Nimrichter L, Rodrigues ML. Gomesin, a peptide produced by the spider Acanthoscurria gomesiana, is a potent anticryptococcal agent that acts in synergism with fluconazole. FEMS Microbiol. Lett. 274(2), 279-286 (2007).
116. Machado A, Fazio MA, Miranda A, Daffre S, Machini MT. Synthesis and properties of cyclic gomesin and analogues. J. Pept. Sci. (2012).
117. Fazio MA, Jouvensal L, Vovelle F et al. Biological and structural characterization of new linear gomesin analogues with improved therapeutic indices. Biopolymers 88(3), 386-400 (2007).
118. Fazio MA, Oliveira VX Jr, Bulet P, Miranda MT, Daffre S, Miranda A. Structure-activity relationship studies of gomesin: importance of the disulfide bridges for conformation, bioactivities, and serum stability. Biopolymers 84(2), 205-218 (2006).
119. Monincova L, Slaninova J, Fucik V et al. Lasiocepsin, a novel cyclic antimicrobial peptide from the venom of eusocial bee Lasioglossum laticeps (Hymenoptera: Halictidae). Amino acids 43(2), 751-761 (2012).
120. Andres E. Cationic antimicrobial peptides in clinical development, with special focus on thanatin and heliomicin. Eur. J. Clin. Microbiol. Infect. Dis. 31(6), 881-888 (2012).
121. Fehlbaum P, Bulet P, Chernysh S et al. Structure-activity analysis of thanatin, a 21-residue inducible insect defense peptide with sequence homology to frog skin antimicrobial peptides. Proc. Natl Acad. Sci. USA 93(3), 1221-1225 (1996).
122. Chomcheon P, Wiyakrutta S, Aree T et al. Curvularides A-E. antifungal hybrid peptide-polyketides from the endophytic fungus Curvularia geniculata. Chemistry 16(36), 11178-11185 (2010).
123. Kabir ME, Karim N, Krishnaswamy S et al. Peptide derived from anti-idiotypic singlechain antibody is a potent antifungal agent compared with its parent fungicide HM-1 killer toxin peptide. Appl. Microbiol. Biotechnol. 92(6), 1151-1160 (2011).
124. Mandal SM, Migliolo L, Franco OL, Ghosh AK. Identification of an antifungal peptide from Trapa natans fruits with inhibitory effects on Candida tropicalis biofilm formation. Peptides 32(8), 1741-1747 (2011).
125. Sengupta J, Saha S, Khetan A, Sarkar SK, Mandal SM. Effects of lactoferricin B against keratitis-associated fungal biofilms. J. Infect. Chemother. (2012).
126. Ahlers JD, Belyakov IM. Memories that last forever: strategies for optimizing vaccine T-cell memory. Blood 115(9), 1678-1689 (2010).
127. Hickman HD, Bennink JR, Yewdell JW. From optical bench to cageside: intravital microscopy on the long road to rational vaccine design. Immunol. Rev. 239(1), 209-220 (2011).
128. Picker LJ, Hansen SG, Lifson JD. New paradigms for HIV/AIDS vaccine development. Ann. Rev. Med. 63, 95-111 (2012).
129. Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities. Expert Opin. Ther. Pat. 22(4), 391-415 (2012).
130. Maggiorella MT, Baroncelli S, Michelini Z et al. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine 22(25-26), 3258-3269 (2004).
131. Pastey MK, Gower TL, Spearman PW, Crowe JE Jr, Graham BS. A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3. Nat. Med. 6(1), 35-40 (2000).
132. Barlow PG, Svoboda P, Mackellar A et al. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS ONE 6(10), e25333 (2011).
133. Liang QL, Zhou K, He HX. Retrocyclin 2: a new therapy against avian influenza H5N1 virus in vivo and vitro. Biotechnol. Lett 32(3), 387-392 (2010).
134. Cole AM, Patton DL, Rohan LC et al. The formulated microbicide RC-101 was safe and antivirally active following intravaginal application in pigtailed macaques. PLoS ONE 5(11), e15111 (2010).
135. Nicol MQ, Ligertwood Y, Bacon MN, Dutia BM, Nash AA. A novel family of peptides with potent activity against influenza A viruses. J. Gen. Virol. 93(Pt 5), 980-986 (2012).
136. Jones JC, Turpin EA, Bultmann H, Brandt CR, Schultz-Cherry S. Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells. J. Virol. 80(24), 11960-11967 (2006).
137. Huang HN, Rajanbabu V, Pan CY et al. Modulation of the immune-related gene responses to protect mice against Japanese encephalitis virus using the antimicrobial peptide, tilapia hepcidin 1-5. Biomaterials 32(28), 6804-6814 (2011).
138. Zhao Z, Hong W, Zeng Z et al. Mucroporin-M1 inhibits hepatitis B virus replication by activating the mitogenactivated protein kinase (MAPK) pathway and down-regulating HNF4alpha in vitro and in vivo. J. Biol. Chem. 287(36), 30181-30190 (2012).
139. ElSawy KM, Twarock R, Verma CS, Caves LS. Peptide inhibitors of viral assembly: a novel route to broad-spectrum antivirals. J. Chem. Inf. Model. 52(3), 770-776 (2012).
140. Eade CR, Wood MP, Cole AM. Mechanisms and modifications of naturally occurring host defense peptides for anti-HIV microbicide development. Curr. HIV Res. 10(1), 61-72 (2012).
141. Ashkenazi A, Wexler-Cohen Y, Shai Y. Multifaceted action of Fuzeon as virus-cell membrane fusion inhibitor. Biochim. Biophys. Acta 1808(10), 2352-2358 (2011).
142. Williams IG. Enfuvirtide (Fuzeon): the first fusion inhibitor. Int. J. Clin. Pract. 57(10), 890-897 (2003).
143. Joly V, Jidar K, Tatay M, Yeni P. Enfuvirtide: from basic investigations to current clinical use. Expert Opin. Pharmacother. 11(16), 2701-2713 (2010).
144. Schneider SE, Bray BL, Mader CJ et al. Development of HIV fusion inhibitors. J. Pept. Sci. 11(11), 744-753 (2005).
145. Bray BL. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat. Rev. Drug Discov. 2(7), 587-593 (2003).
146. Chong H, Yao X, Zhang C et al. Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PLoS ONE 7(3), e32599 (2012).
147. Keogan S, Passic S, Krebs FC. Infection by CXCR4-tropic human immunodeficiency virus type 1 is inhibited by the cationic cell-penetrating peptide derived from HIV-1 tat. Int. J. Pept. 2012, 349427 (2012).
148. Dewan V, Liu T, Chen KM et al. Cyclic peptide inhibitors of HIV-1 capsid-human lysyl-tRNA synthetase interaction. ACS Chem. Biol. 7(4), 761-769 (2012).
149. Li GR, He LY, Liu XY et al. Rational design of peptides with anti-HCV/HIV activities and enhanced specificity. Chem. Biol. Drug Des. 78(5), 835-843 (2011).
150. Bocanegra R, Nevot M, Domenech R et al. Rationally designed interfacial peptides are efficient in vitro inhibitors of HIV-1 capsid assembly with antiviral activity. PLoS ONE 6(9), e23877 (2011).
151. Maselko M, Ward C, Pastey M. A RhoA-derived peptide inhibits human immunodeficiency virus-1 entry in vitro. Curr. HIV Res. 9(1), 1-5 (2011).
152. Pan XB, Wei L, Han JC, Ma H, Deng K, Cong X. Artificial recombinant cell-penetrating peptides interfere with envelopment of hepatitis B virus nucleocapsid and viral production. Antiviral research 89(1), 109-114 (2011).
153. Si Y, Liu S, Liu X et al. A human claudin-1- derived peptide inhibits hepatitis C virus entry. Hepatology 56(2), 507-515 (2012).
154. Montero A, Gastaminza P, Law M, Cheng G, Chisari FV, Ghadiri MR. Self-assembling peptide nanotubes with antiviral activity against hepatitis C virus. Chem. Biol. 18(11), 1453-1462 (2011).
155. Hong HW, Lee SW, Myung H. Selection of peptides binding to HCV e2 and inhibiting viral infectivity. J. Microbiol. Biotechnol. 20(12), 1769-1771 (2010).
156. Doss M, Ruchala P, Tecle T et al. Hapivirins and diprovirins: novel theta-defensin analogs with potent activity against influenza A virus. J. Immunol. 188(6), 2759-2768 (2012).
157. Jones JC, Settles EW, Brandt CR, Schultz- Cherry S. Identification of the minimal active sequence of an anti-influenza virus peptide. Antimicrob. Agents Chemother. 55(4), 1810-1813 (2011).
158. Wunderlich K, Juozapaitis M, Ranadheera C et al. Identification of high-affinity PB1- derived peptides with enhanced affinity to the PA protein of influenza A virus polymerase. Antimicrob. Agents Chemother. 55(2), 696-702 (2011).
159. Nitsche C, Behnam MA, Steuer C, Klein CD. Retro peptide-hybrids as selective inhibitors of the Dengue virus NS2B-NS3 protease. Antiviral Res. 94(1), 72-79 (2012).
160. Miller EH, Harrison JS, Radoshitzky SR et al. Inhibition of Ebola virus entry by a C-peptide targeted to endosomes. J. Biol. Chem. 286(18), 15854-15861 (2011).
161. Melnik LI, Garry RF, Morris CA. Peptide inhibition of human cytomegalovirus infection. Virology J. 8, 76 (2011).
162. Luganini A, Nicoletto SF, Pizzuto L et al. Inhibition of herpes simplex virus type 1 and type 2 infections by peptide-derivatized dendrimers. Antimicrob. Agents Chemother. 55(7), 3231-3239 (2011).
163. De Witte L, Bobardt MD, Chatterji U et al. HSV neutralization by the microbicidal candidate C5A. PLoS ONE 6(5), e18917 (2011).
164. Tian C, Gao B, Rodriguez Mdel C, Lanz- Mendoza H, Ma B, Zhu S. Gene expression, antiparasitic activity, and functional evolution of the drosomycin family. Mol. Immunol. 45(15), 3909-3916 (2008).
165. Zhang ZT, Zhu SY. Drosomycin, an essential component of antifungal defence in Drosophila. Insect Mol. Biol. 18(5), 549-556 (2009).
166. Ullal AJ, Noga EJ. Antiparasitic activity of the antimicrobial peptide HbbetaP-1, a member of the beta-haemoglobin peptide family. J. Fish Dis. 33(8), 657-664 (2010).
167. Salay LC, Nobre TM, Colhone MC et al. Dermaseptin 01 as antimicrobial peptide with rich biotechnological potential: study of peptide interaction with membranes containing Leishmania amazonensis lipid-rich extract and membrane models. J. Pept. Sci. 17(10), 700-707 (2011).
168. Herculano RD, Pavinatto FJ, Caseli L, D'silva C, Oliveira ON Jr. The lipid composition of a cell membrane modulates the interaction of an antiparasitic peptide at the air-water interface. Biochim. Biophys. Acta 1808(7), 1907-1912 (2011).
169. Pascholati CP, Lopera EP, Pavinatto FJ et al. The interaction of an antiparasitic peptide active against African sleeping sickness with cell membrane models. Colloids Surf. 74(2), 504-510 (2009).
170. Arrighi RB, Ebikeme C, Jiang Y et al. Cell-penetrating peptide TP10 shows broad-spectrum activity against both Plasmodium falciparum and Trypanosoma brucei brucei. Antimicrob. Agents Chemother. 52(9), 3414-3417 (2008).
171. Villa-Hernandez O, Hernandez-Orihuela L, Del Carmen Rodriguez M et al. Novel antimicrobial peptides isolated from skin secretions of the Mexican frog Hyla eximia. Protein Pept. Lett. 16(11), 1371-1378 (2009).
172. Lofgren SE, Miletti LC, Steindel M, Bachere E, Barracco MA. Trypanocidal and leishmanicidal activities of different antimicrobial peptides (AMPs) isolated from aquatic animals. Exp. Parasitol. 118(2), 197-202 (2008).
173. Zhang Z, Zhu S. Functional role of charged residues in drosomycin, a Drosophila antifungal peptide. Dev. Comp. Immunol. 34(9), 953-958 (2010).
174. Clinical Trials. www.clinicaltrials.gov
175. Cubist Pharmaceuticals. www.cubist.com
176. MerLion Pharmaceuticals. www.merlionpharma.com
177. Novacta. www.novactabio.com
178. Oragenics. www.oragenics.com
179. PMLiVE. Meeting with resistance. www.pmlive.com/pharma-news/meeting- with-resistance-262262
180. Safety of Human Lactoferrin hLF1-11 for the Treatment of Infectious Complications Among Haematopoietic Stem Cell Transplant Recipients. http://clinicaltrials.gov/ct2/show/ NCT00430469
181. Inimex. Technology overview and status. www.inimexpharma.com/prod-tech- profile. html